The effect of CYP2C19 polymorphism on the pharmacokinetics and acid-inhibitory effects of oral lansoprazole and omeprazole

被引：0
|
作者：
Bekkers, CHJ
Touw, DJ
Lamers, CBHW
Geus, WP
机构：
[1] Hague Cent Pharm, The Hague, Netherlands
[2] Leiden Univ, Med Ctr, NL-2300 RA Leiden, Netherlands
[3] Leyenburg Hosp, The Hague, Netherlands
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2002年 / 54卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：553 / 553
页数：1
相关论文
共 50 条
  • [41] EFFECT OF CYP2C19 POLYMORPHISM ON THE PHARMACOKINETICS OF ROSUVASTATIN IN HEALTHY TAIWANESE SUBJECTS.
    Wang, Y.
    Wang, T.
    Finkelman, R. D.
    Jou, H.
    Azumaya, C. T.
    Mosqueda-Garcia, R.
    Birmingham, B. K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S22 - S22
  • [42] Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism
    Takahashi, K
    Motohashi, H
    Yonezawa, A
    Okuda, M
    Ito, N
    Yamamoto, S
    Ogawa, O
    Inui, K
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (05) : 791 - 794
  • [43] Influence of CYP2C19 Polymorphism on Lansoprazole and Rabeprazole Maintenance Treatment of Reflux Esophagitis
    Koike, Tomoyuki
    Iijima, Katsunori
    Imatani, Akira
    Shimosegawa, Tooru
    GASTROENTEROLOGY, 2010, 138 (05) : S655 - S655
  • [44] Hydroxylation of lansoprazole in poor metabolizers of CYP2C19
    Furuta, T
    Shirai, N
    Sugimoto, M
    Nakamura, A
    Hishida, A
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 61 (03) : 361 - 361
  • [45] Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype
    Kamiya, Chiaki
    Inui, Naoki
    Hakamata, Akio
    Miyakawa, Sachiko
    Tanaka, Shimako
    Uchida, Shinya
    Namiki, Noriyuki
    Odagiri, Keiichi
    Watanabe, Hiroshi
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2019, 139 (04) : 361 - 366
  • [46] Lansoprazole + clarithromycin: interaction independent of CYP2C19
    Reactions Weekly, 2005, 1052 (1) : 3 - 3
  • [47] The effect of famotidine on the acid inhibition by lansoprazole in relation to CYP2C19 genotype status.
    Furuta, T
    Shirai, N
    Sugimoto, M
    Nakamura, A
    Okudaira, K
    Kajimura, M
    Hishida, A
    GASTROENTEROLOGY, 2005, 128 (04) : A426 - A426
  • [48] THE EFFECT OF CYP2C19 POLYMORPHISM ON THE PHARMACOKINETICS AND TOLERABILITY OF VORICONAZOLE AFTER MULTIPLE ORAL ADMINISTRATIONS IN HEALTHY VOLUNTEERS.
    Lee, S.
    Kim, B. H.
    Nam, W. S.
    Kim, S. J.
    Shim, J. H.
    Yoon, S. H.
    Cho, J. Y.
    Shin, S. G.
    Jang, I. J.
    Yu, K. S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S26 - S27
  • [49] Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects (vol 41, pg 511, 2011)
    Zhang, Dan
    Wang, Xiaolin
    Yang, Man
    Wang, Guocai
    Liu, Huichen
    XENOBIOTICA, 2011, 41 (09) : 836 - 836
  • [50] Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans
    Annika Elbe
    Kathrin Isabelle Foerster
    Antje Blank
    Peter Rose
    Jürgen Burhenne
    Walter Emil Haefeli
    Gerd Mikus
    European Journal of Clinical Pharmacology, 2022, 78 : 975 - 987
12345